Trial Profile
A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected subjects treated with HAART
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Abbott Healthcare Products
- 21 Apr 2010 Actual number of patients (51) added as reported by ClinicalTrials.gov record.
- 21 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 15 Feb 2008 New trial record.